Search

Study Design Retrospective study. Purpose The objective of this study was to compare percent correction between apical and periapical pedicle screw (PS) and sublaminar wire constructs for Cobb correction and coronal balance correction. Overview of Literature The current gold standard for deformity correction in adolescent idiopathic scoliosis (AIS) are PS constructs. Sublaminar wires provide an alternative means of fixation when PS fixation cannot be safely performed. Two previous studies have compared percent curve correction between sublaminar wires and PSs, with conflicting conclusions. Methods The study was a retrospective review of Lenke type 1 curves with minimum follow-up of at least 1 year. Cases were divided into two groups: constructs using apical/periapical sublaminar wires (SL group) versus PS only constructs (PS group). Percent Cobb correction and coronal balance were compared between the two groups at 1 year. A multivariable regression model was used to determine the impact of apical/periapical wires on percent Cobb correction and coronal balance at 1 year when accounting for additional variables. Results The cohort included 71 patients who were predominantly female (80.2%), with average age of 14.2 years. Only 21 (29.5%) of constructs utilized apical/periapical sublaminar wires. There was a significant difference in percent Cobb correction at 1 year for the PS and SL groups (70.26% vs. 60.09%, p=0.05). No difference was observed in overall coronal balance. A multivariable model revealed that apical/periapical wires were negatively associated with percent Cobb correction at 1 year (coefficient=−8.49, p=0.023), while total implant density of the construct was positively associated with correction (coefficient=24.2, p

The regioselective addition of Grignard reagents to mono- and disubstituted N-acylpyrazinium salts affording substituted 1,2-dihydropyrazines in modest to excellent yields (45–100%) is described. Under acidic conditions, these 1,2-dihydropyrazines can be converted to substituted Δ5-2-oxopiperazines providing a simple and efficient approach towards their preparation.

Background. Neurological complications are common after lung transplantation. However, no large cohort studies have examined the incidence, predictors, and clinical significance of neurological events sustained by lung transplant recipients. Methods. We conducted a retrospective cohort analysis of a consecutive series of lung transplant recipients, transplanted at Duke University Medical Center between May 2014 and February 2017 (n = 276). Early neurological complications (ie, occurring during the first week after transplant) were documented by transplant mental health specialists and included delirium, ischemic injury, and posterior reversible encephalopathy syndrome. Analyses accounted for age, native disease, sex, type of transplant, lung allocation score, and primary graft dysfunction. The objectives of the study were to characterize the prevalence and predictors of early neurological sequelae (NSE), occurring during the first week posttransplant, and the association between NSE and subsequent clinical outcomes, including length of stay and mortality. Results. Neurological sequelae were common, occurring in 123 (45%) patients. Fifty-seven patients died over a follow-up interval of 2.1 years. The most common NSE were postoperative delirium (n = 110 [40%]) and posterior reversible encephalopathy syndrome (n = 12 [4%]), followed by stroke/transient ischemic attack and neurotoxicity. Higher lung allocation score was the strongest predictor of delirium. The presence of a NSE was associated with longer length of hospital stay (32 days vs 17 days, P < 0.001) and greater mortality (hazard ratio, 1.90; 95% confidence interval, 1.09-3.32], P = 0.024), with the greatest mortality risk occurring approximately 2 years after transplantation. Conclusions. Neurological events are relatively common after lung transplantation and associated with adverse clinical outcomes.

Throughout the history of human spaceflight, spacefarers have experienced and reported the occurrence ofmedical conditions, including various illnesses and injuries. Therefore, future spaceflight missions to the Moon and Mars will require the capabilities necessary for maintaining the health of these new space travelers. Mass, power, and volume available in the space vehicles used for these missions will be severely constrained. The ability to resupply or evacuate to Earth will be limited or non-existent, and ground-based support will no longer be immediate due to communication latencies and blackouts. These vehicle and mission constraints will necessitate healthcare be provided from an efficiently planned medical system. To provide the necessary care, thesemedical systemswill need to include at aminimum, several different types of medical devices, consumable resources, centralized data management, procedural guidance, and decision support technologies. Medical devices needed for diagnosing and treating medical conditions that are expected to occur during future spaceflight missions may include real-time health monitoring, medical imaging capabilities, as well as blood and urine analysis. Novel methods for interacting with onboard patient medical records will be necessary, as will resource tracking. Terrestrial medicine sharesmany of these same needs, therefore a multitude of these required medical capabilities can likely be satisfied by currently available, Commercial-Off-The-Shelf (COTS) devices and methodologies; however, in some cases the unique space environment and increased mission durations will drive the need for modifications or customization of standard technologies and treatment procedures. This article will provide a review of medical devices and technologies that have been considered for inclusion within future spaceflight medical systems. It will also include a discussion about the modifications and customized development that have been performed, as well as descriptions of the technology demonstrations that have been conducted in analog and spaceflight environments. [ABSTRACT FROM AUTHOR]

Abstract Background Father involvement, defined in terms of both the quantity and quality of ways in which fathers may be involved, affects the child’s development. How specifically father involvement links to emotion regulation during early childhood (0–5 years) is, however, less clear. Methods This literature review synthesizes research on the links between father involvement and emotion regulation during early childhood, as well as the measurement methods used to assess them. Ten relevant studies were identified via four databases (up to August 2023). Results Results showed no significant direct links, but significant links appeared between high father involvement and more adaptive emotion regulation when moderated by variables related to the assessment of father involvement and emotion regulation, as well as the characteristics of the father and the child. Conclusions Future research should continue to use observational measures of father behaviors and child emotion regulation, increase the use of physiological measures of emotion regulation, and consider the influence of maternal and family variables.

Not available.

Objectives: Arterial hypertension (HTN) is considered a seminal risk factor for aortic dissection (AD). The purpose of this study is to evaluate whether pre-existing blood pressure (BP) control lessens the extent of dissection and has a favorable impact on outcome of patients with acute AD. Methods: Consecutive acute AD patients who had at least two BPs recorded within the 12 months preceding the AD were retrospectively analyzed. The two most recent BPs were averaged and defined per published guidelines as normal (BP≤ 130/80), Stage I HTN (BP >130/80 and <139/89), or Stage 2 or greater HTN (BP > 140/90). The number of hypertensive medications (MEDs) was also used as a surrogate marker of HTN severity. Patients with known genetic causes of AD were excluded. Results: 89 subjects (55% men, 45% women; mean age, 64±14 years) with acute AD (58% Stanford type A and 42% Stanford type B) were included. Two most recent BPs were recorded a mean of 5±3 and 3±2.7 months before the AD, respectively. Twenty-nine (33%) subjects had normal BP, including nine subjects with no history of HTN and on no MEDs. Sixty (67%) subjects had elevated BP, including 21 (35%) with Stage I HTN and 39 (65%) with Stage 2 HTN. Compared to subjects with normal BP, subjects with Stage 1 and Stage 2 HTN were younger (70±13 years vs 62±1 year, p = 0.01), but there were no differences in other demographics, risk factors, comorbidities, or history of drug use. There were no group differences in the distal extent of the dissections, complications requiring thoracic endograft repair, mean length of hospital stay, final discharge status, or 30-day mortality. Compared to the number of MEDs before AD, all three groups had a higher mean number of MEDs to achieve normal BP at discharge that persisted at a mean follow-up of 18±15 months. Conclusions: These data show that approximately one-third of patients with acute AD had well controlled or no antecedent history of HTN. The degree of pre-existing HTN control had no bearing on the type or extent of AD, length of stay, or early outcome. Regardless of the state of HTN control before AD, the consistent and sustained increase in the severity of HTN after AD suggests that the dissection process has a profound and lasting effect on BP regulation. Further studies are indicated to elucidate the pathologic mechanisms involved in AD. [ABSTRACT FROM AUTHOR]